title: A retrospective study of growth hormone use in adolescents with cystic fibrosis.
abstract: OBJECTIVE
  Studies of growth hormone (GH) effectiveness in prepubertal children with cystic fibrosis (CF) have been published previously. We present a retrospective study of GH treatment in adolescents with CF.
  
  
  METHODS
  We performed a retrospective evaluation of data from 25 pubertal adolescents (ages 13 years 4 months to 16 years 11 months, Tanner stage III or IV). Thirteen (4 F) were followed for 1 year, then received 1 year of treatment with GH (GHTX). We compared the results with a 'control' group of 12 (4 F) whose growth was followed for 1 year (NonTX) but who were not treated with GH at the time of this review. Anthropometric data included: height, weight, lean tissue mass (LTM) and bone mineral content (BMC). Pulmonary function, number of hospitalizations, glycosylated haemoglobin (HbA1c), random blood glucose levels, IGF-I, oestradiol and testosterone levels are also reported.
  
  
  RESULTS
  There was no difference between the groups at baseline. After 1 year, GHTX had significantly greater height and weight velocity, height and weight Z-scores, body mass index (BMI), LTM and BMC. Absolute pulmonary function was better and hospitalizations were fewer in the GHTX. No subject developed glucose intolerance or had any other side-effects.
  
  
  CONCLUSIONS
  These results suggest that GH use in pubertal adolescents with CF safely improves height, body weight, bone mineralization and clinical status.
authors.affiliation: Department of Pediatrics, University of Texas South-Western Medical School, Dallas, TX 75390-9063, USA. dana.hardin@utsouth-western.edu
authors.forename: Dana S
authors.initials: DS
authors.lastname: Hardin
authors.forename: Tom
authors.initials: T
authors.lastname: Ferkol
authors.forename: Chul
authors.initials: C
authors.lastname: Ahn
authors.forename: Daina
authors.initials: D
authors.lastname: Dreimane
authors.forename: Maynard
authors.initials: M
authors.lastname: Dyson
authors.forename: Martha
authors.initials: M
authors.lastname: Morse
authors.forename: Claude
authors.initials: C
authors.lastname: Prestidge
authors.forename: Julie
authors.initials: J
authors.lastname: Rice
authors.forename: Dan K
authors.initials: DK
authors.lastname: Seilheimer
mesh_terms: D000293:Adolescent; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition; D001827:Body Height / Q000187:drug effects; D015992:Body Mass Index; D015519:Bone Density; D016022:Case-Control Studies; D003550:Cystic Fibrosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004958:Estradiol / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006760:Hospitalization; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008168:Lung / Q000503:physiopathology; D008297:Male; D012189:Retrospective Studies; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D015430:Weight Gain
chemical_list: D001786:Blood Glucose; D004958:Estradiol; D006442:Glycated Hemoglobin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D013739:Testosterone